The European Commission has granted conditional marketing authorization (Aic) for idecabtagene vicleucel (Ide-cel), the first T-cell based immunotherapy with chimeric antigen receptor (Car-T) directed against maturation antigen B cell (Bcma), for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and who have demonstrated disease progression to the last therapy. This was announced by Bristol Myers Squibb (Bms), noting that Ide-cel is the first and only approved Car-T therapy aimed at recognizing and binding to Bcma, a protein almost universally expressed on multiple myeloma cells, killing diseased cells.
Read Also
- Third dose Covid vaccine, Lancet: “Not for everyone” Sep 13, 2021
- The Delta variant threatens the entry into force of the covid certificate Jul 1, 2021
- WHO identifies pathogens that may cause future pandemics Nov 21, 2022
- At the Gemelli JCI accreditation, the ‘stamp’ of world excellence in healthcare Jul 14, 2021
- US sent two million doses of coronavirus vaccine to Ukraine Jul 16, 2021
- More than 4.8 million people were vaccinated against coronavirus in Moscow Sep 9, 2021
- Medicine shortage: Are you worried that you won’t be able to treat yourself properly this winter? Nov 19, 2022